Veradermics Seeks FDA Approval for Hair Loss Therapy VDPHL01
The latest in this situation
How it started
What happened
Veradermics, Incorporated is seeking approval from the FDA for its lead therapy, VDPHL01, which targets hair loss. The company recently released positive Phase 3 trial results for VDPHL01, an extended-release minoxidil formulation. In the study, 78.8% of patients on the daily dose and 85% on the twice-daily dose reported improvements in hair coverage compared to 35.3% in the placebo group.
From fool.com
Why it matters
If approved, VDPHL01 could become the first non-hormonal oral therapeutic for pattern hair loss and the first oral minoxidil approved in nearly three decades. This drug would serve as an alternative to finasteride, which is currently the only approved oral prescription for hair loss but works hormonally and has side effects.
From fool.com
Who's involved
- FDARegulatory agency reviewing the drug application
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- VDPHL01 drug application requires review by FDA's drug evaluation centerThe Center for Drug Evaluation and Research must review VDPHL01's application for hair loss treatment.Likely
- How could the potential FDA approval of VDPHL01 affect Eli Lilly and Company?New hair loss treatment could increase competition for major pharma playersPossible
- New hair loss drug application may prompt congressional oversightPotential approval of new hair loss drug may prompt congressional oversightPossible
How it developed
Newest first. Tap a step to see who reported it.- Pooja Shah commented on positive phase 3 data for Veradermics and VDPHL01, a Connecticut-based biopharmaceutical company.Sub-event
VDPHL01 and Veradermics are seeking FDA approval for hair loss treatments, offering alternatives to finasteride.1 source
Keep exploring
The entities involved
Related events
- FDA approved a drug based on UVA research led by Xuemei Huang.
- FDA granted clearance for DVT treatment involving Penumbra, Inc.
- Research advances have led to the approval of new therapies by the FDA.
- Merck announced on September 3, 2025, that it is seeking potential approval for new drugs from the FDA.